Hydrocortisonum Pharmaswiss (Hydrocortisone Acetate)

Hydrocortisonum Pharmaswiss is indicated for several ocular inflammatory disorders where reduction of swelling, redness, and pain is required.

• Acute anterior uveitis to control intra‑ocular inflammation and prevent synechiae formation
• Post‑operative inflammation after cataract or refractive surgery to reduce corneal edema and pain
• Allergic conjunctivitis that does not respond adequately to topical antihistamines
• Non‑infectious keratitis where inflammatory infiltrates contribute to epithelial damage
• Severe dry‑eye syndrome with marked inflammatory signs requiring steroidal therapy
• Ocular inflammation linked to systemic autoimmune conditions such as rheumatoid arthritis

• Hydrocortisonum Pharmaswiss delivers hydrocortisone acetate to ocular tissues, where the compound penetrates cell membranes and binds to intracellular glucocorticoid receptors. The receptor‑ligand complex translocates to the nucleus and interacts with glucocorticoid response elements, altering gene transcription. This down‑regulates pro‑inflammatory cytokines, inhibits phospholipase A₂ activity, and reduces vascular permeability, collectively suppressing the inflammatory cascade in the eye.

Like other topical corticosteroids, Hydrocortisonum Pharmaswiss may cause local and systemic adverse reactions, most of which are dose‑ and duration‑dependent.

Common

• Transient ocular burning or stinging on instillation
• Mild conjunctival hyperemia
• Temporary increase in intra‑ocular pressure (IOP) that resolves after discontinuation
• Slight blurred vision after dosing
• Superficial corneal epithelial irritation

Serious

• Persistent elevation of IOP leading to glaucoma
• Cataract formation with prolonged use
• Secondary ocular infection (bacterial, fungal, or viral)
• Delayed wound healing after ocular surgery
• Hypersensitivity reactions such as severe eyelid edema or rash

Appropriate use of Hydrocortisonum Pharmaswiss requires attention to patient history, treatment duration, and monitoring to minimize risks.

• Avoid use in patients with known viral ocular infections (e.g., herpes simplex keratitis) unless antiviral therapy is also administered
• Monitor intra‑ocular pressure regularly, especially in glaucoma suspects or patients with a history of steroid‑responsive IOP rise
• Limit treatment duration; long‑term therapy increases risk of cataract and glaucoma
• Use with caution in children, as they may be more susceptible to steroid‑induced IOP elevation
• Discontinue if signs of secondary infection appear, such as purulent discharge or worsening redness
• Counsel patients to report persistent visual changes or eye pain promptly

Hydrocortisonum Pharmaswiss can interact with other ophthalmic agents, potentially altering efficacy or safety.

Avoid

• Concurrent use of other topical corticosteroids, which may amplify IOP elevation risk
• Combination with potent ocular vasoconstrictors that could exacerbate ocular surface irritation
• Simultaneous administration of topical non‑steroidal anti‑inflammatory drugs (NSAIDs) without physician guidance, due to additive corneal toxicity

Use with caution

• Systemic corticosteroids, as combined systemic and topical exposure may increase systemic absorption
• Antiviral eye drops (e.g., acyclovir) when treating herpetic keratitis; steroids may suppress immune response
• Antifungal eye preparations, requiring close monitoring for infection progression
• Beta‑blocker eye drops, as both may affect IOP measurements